Heterogeneity of triple negative breast cancer: Current advances in subtyping and treatment implications.

ABSTRACT: As the field of translational 'omics has progressed, refined classifiers at both genomic and proteomic levels have emerged to decipher the heterogeneity of breast cancer in a clinically-applicable way. The integration of 'omics knowledge at the DNA, RNA and protein levels is further expanding biologic understanding of breast cancer and opportunities for customized treatment, a particularly pressing need in clinically triple negative tumors. For this group of aggressive breast cancers, work from multiple groups has now validated at least four major biologically and clinically distinct omics-based subtypes. While to date most clinical trial designs have considered triple negative breast cancers as a single group, with an expanding arsenal of targeted therapies applicable to distinct biologic

SUBMITTER: Asleh K 

PROVIDER: S-EPMC9434975 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature